An automated flow system incorporating in-line acid dissolution of bismuth metal from a cyclotron irradiated target assembly for use in the isolation of astatine-211

Targeted α particle immunotherapy for myeloid leukemia

Joseph G. Jurcic, Steven M. Larson, George Sgouros et al. · Blood · 2002 · 467 citations · Full text

Medicine, Hematology, Oncology +14

Clinical Experience with α-Particle–Emitting ²¹¹At: Treatment of Recurrent Brain Tumor Patients with ²¹¹At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6

Michael R. Zalutsky, David A. Reardon, Gamal Akabani et al. · Journal of Nuclear Medicine · 2007 · 396 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Intraperitoneal α-Particle Radioimmunotherapy of Ovarian Cancer Patients: Pharmacokinetics and Dosimetry of ²¹¹At-MX35 F(ab′)₂—A Phase I Study

Håkan Andersson, Elin Cederkrantz, Tom Bäck et al. · Journal of Nuclear Medicine · 2009 · 288 citations · Full text

Medicine, Oncology, Pharmacokinetics +17

Sequential Cytarabine and α-Particle Immunotherapy with Bismuth-213–Lintuzumab (HuM195) for Acute Myeloid Leukemia

Todd Rosenblat, Michael R. McDevitt, Deborah Mulford et al. · Clinical Cancer Research · 2010 · 264 citations · Full text

Medicine, Hematology, Oncology +17

The promise of targeted {alpha}-particle therapy.

Deborah Mulford, David A. Scheinberg, Joseph G. Jurcic · PubMed · 2005 · 164 citations

Medicine, Nuclear Medicine, Oncology +17